Guruprasad R. Medigeshi

About

Our group focuses flaviviruses and our research interest is in characterising the immune response and host-pathogen interactions in dengue infection. We have established hospital-based and community-based cohorts to understand the role of circulating dengue viruses, inflammation and immune response in primary and secondary dengue infections. We also focus on antiviral development for RNA viruses.

Employment

• Indian Institute of Science Education and Research, Tirupati Professor
  2024 - Present
• Translational Health Science and Technology Institute Professor
  2020 - 2024
• Translational Health Science and Technology Institute Associate Professor
  2014 - 2019
• Translational Health Science and Technology Institute Assistant Professor
  2009 - 2014

Education

• Georg-August-Universität Göttingen Ph.D.
  1999 - 2003

Projects & Funding

Projects & funding information is unavailable.

Publications (70)

• Respiratory Syncytial Virus F Protein Adjuvanted with a Carbomer-Based Adjuvant Induces Protective Humoral Response in Mice
  ACS Omega 2026 DOI: 10.1021/acsomega.5c08819
  +Save
• The Effective Inhibitory Concentration of Interferon-β Correlates with Infectivity and Replication Fitness of SARS-CoV-2 Variants
  Journal of Interferon & Cytokine Research 2024 DOI: 10.1089/jir.2024.0016
  +Save
• Long-Term Kinetics of SARS-CoV-2 Neutralizing and Anti-Receptor Binding Domain Antibodies among Laboratory-Confirmed COVID-19 Cases in Delhi National Capital Region, India: A Prospective, One-Year Follow-Up Study
  Journal of Clinical Medicine 2024 DOI: 10.3390/jcm13030762
  +Save
• Integrative analysis discovers Imidurea as dual multitargeted inhibitor of CD69, CD40, SHP2, lysozyme, GATA3, cCBL, and S-cysteinase from SARS-CoV-2 and M. tuberculosis
  International Journal of Biological Macromolecules 2024 DOI: 10.1016/j.ijbiomac.2024.132332
  +Save
• Anti-SARS-CoV-2 Antibody Kinetics up to 6 months of follow-up: Result from a Nation-wide Population-based, Age Stratified Sero-Epidemiological Prospective Cohort Study in India
  2023 DOI: 10.1101/2023.06.15.23291475
  +Save
• Antibody Response to SARS-CoV-2 among COVID-19 Confirmed Cases and Correlates with Neutralizing Assay in a Subgroup of Patients in Delhi National Capital Region, India
  Vaccines 2022 DOI: 10.3390/vaccines10081312
  +Save
• A Vitamin D–RelB/NF-κB Pathway Limits Chandipura Virus Multiplication by Rewiring the Homeostatic State of Autoregulatory Type 1 IFN–IRF7 Signaling
  The Journal of Immunology 2022 DOI: 10.4049/jimmunol.2101054
  +Save
• Pre-existing antibody levels negatively correlate with antibody titers after a single dose of BBV152 vaccination
  Nature Communications 2022 DOI: 10.1038/s41467-022-31170-1
  +Save
• Sub-optimal neutralisation of omicron (B.1.1.529) variant by antibodies induced by vaccine alone or SARS-CoV-2 Infection plus vaccine (hybrid immunity) post 6-months
  eBioMedicine 2022 DOI: 10.1016/j.ebiom.2022.103938
  +Save
• Selection of optimum formulation of RBD-based protein sub-unit covid19 vaccine (Corbevax) based on safety and immunogenicity in an open-label, randomized Phase-1 and 2 clinical studies
  2022 DOI: 10.1101/2022.03.08.22271822
  +Save